Emcure Secures Interim Relief from FDC Ban Amid Regulatory Controversy

Emcure Pharmaceuticals has become one of the first companies to secure interim relief from the Indian government’s recent ban on the sale and distribution of certain fixed-dose combinations (FDCs). The ban, issued by the Union Health Ministry on August 12, 2024, targeted Emcure’s pain relief FDC of S (+)-Etodolac + paracetamol, prohibiting its manufacture and distribution with immediate effect. In response, Emcure filed a writ petition with the Delhi High Court, seeking to overturn the ban.

During the court proceedings, Emcure’s senior counsel argued that the sub-committee report, which formed the basis for the ban, has not been publicly disclosed, leaving the rationale for the complete prohibition unclear. The counsel also referenced a similar case from July 2023 involving Lupin’s FDC (Phenytoin + Phenobarbitone Sodium), where the court granted interim protection for drugs already in distribution.

On August 22, 2024, the Delhi High Court ruled in favor of Emcure, applying the interim order from June 2023 to the current case. The court ordered that while no fresh manufacture of the banned FDC would be permitted, drugs already in the distribution network could remain until the next hearing. Emcure was also directed to submit an affidavit detailing the stock of these FDCs within a week.

This case may signal a repeat of previous FDC prohibitions, dating back to 2016 when 344 FDCs were banned. After a legal challenge, the matter was reviewed by the Drugs Technical Advisory Board (DTAB), which upheld the ban on 328 of these drugs in 2018. The cycle of bans and legal battles continued in 2023, with several companies challenging similar prohibitions.

While some industry leaders, like Sudarshan Jain, Secretary General of the Indian Pharmaceutical Alliance, have supported the recent ban as a necessary step for patient safety, other industry associations are preparing to follow Emcure’s lead. They plan to file appeals to allow the sale of existing stock and challenge the basis of the ban on FDCs deemed "irrational."

This ongoing controversy raises questions about the initial approval process for FDCs and whether authorities fully evaluated their therapeutic benefits and potential risks. The ease of access to medication in India, where many drugs can be purchased without a prescription, underscores the need for stricter oversight to prevent the misuse of potentially harmful combinations.